Anti-China Biotech Policy

BioCentury’s deep dive into U.S.-China life sciences public policy, from the Biosecure Act to executive orders.

BioCentury’s reporting brings readers inside Congress and the White House as legislators and government officials seek to balance national security, commercial competition, privacy and geopolitical rivalry.

Sign up now (free) to access the featured stories below and put BioCentury to work for you.